Navigation Links
A cluster bomb for cancer care
Date:8/23/2010

Chemotherapy, while an effective cancer treatment, also brings debilitating side effects such as nausea, liver toxicity and a battered immune system.

Now, a new way to deliver this life-saving therapy to cancer patients ― getting straight to the source of the disease has been invented by Dr. Dan Peer of Tel Aviv University's Department of Cell Research and Immunology and the Center for Nano Science and Nano Technology together with Prof. Rimona Margalit of the Department of Biochemistry and Molecular Biology.

Drs. Peer and Margalit have developed a nano-sized vehicle with the ability to deliver chemotherapy drugs directly into cancer cells while avoiding interaction with healthy cells, increasing the efficiency of chemotherapeutic treatment while reducing its side effects.

"The vehicle is very similar to a cluster bomb," explains Dr. Peer. Inside the nano-vehicle itself are tiny particles of chemotherapy drugs. When the delivery vehicle comes into contact with cancer cells, it releases the chemotherapeutic payload directly into the cell. According to Dr. Peer, the nanomedical device can be used to treat many different types of cancer, including lung, blood, colon, breast, ovarian, pancreatic, and even several types of brain cancers.

Their technological breakthrough was recently reported in the journal Biomaterials.

A sweet payload to trick cancer

The key to the drug delivery platform is the molecule used to create the outer coating of this cluster nano-vehicle, a sugar recognized by receptors on many types of cancer cells. "When the nano-vehicle interacts with the receptor on the cancerous cell, the receptor undergoes a structural change and the chemotherapy payload is released directly into the cancer cell," says Dr. Peer, which leads to more focused chemotherapeutic treatment against the diseased cells.

Because the nano-vehicle reacts only to cancer cells, the healthy cells that surround them remain untouched and unaffected by the therapy. The nano-vehicle itself, adds Dr. Peer, is made from organic materials which fully decompose in the body once it has performed its function, making the treatment safer than current therapies.

Clinical trials coming soon

This drug will be an improvement on anything currently on the market, says Dr. Peer. Delivering chemotherapeutics directly into cancerous cells themselves is not only more potent, but also much safer.

Drs. Peer and Margalit are working with ORUUS Pharma in California, which has licensed the "cluster bomb" platform from the university and can ensure a quick transition from the lab to clinical trials, which should begin in two years or less, says Dr. Peer.


'/>"/>

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University
Source:Eurekalert  

Related biology news :

1. Tufts wins NCRR grant for Collaborative Cluster in Genome Structure and Developmental Patterning
2. Autism Speaks responds to recent publications citing autism clusters in California
3. Nature study demonstrates that bacterial clotting depends on clustering
4. Understanding cancer using the fruit fly
5. Protein made by breast cancer gene purified
6. Scientists find new twist on drug screening to treat common childhood cancer
7. MSU project may lead to new approaches against lung cancer
8. New mechanisms of tumor resistance to targeted therapy in lung cancer are discovered
9. Research could change course of treatment for cancer that spreads to bones
10. New breast cancer committee to establish federal research agenda
11. Gallbladder cancer may be linked to estrogens, says UH team
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A cluster bomb for cancer care
(Date:3/10/2016)... , March 10, 2016 ... new market research report "Identity and Access Management Market ... Audit, Compliance, and Governance), by Organization Size, by Deployment, ... 2020", published by MarketsandMarkets, The market is estimated to ... 12.78 Billion by 2020, at a Compound Annual Growth ...
(Date:3/8/2016)... , March 8, 2016   Valencell , ... today announced it has secured $11M in Series ... Tech, a new venture fund being launched by ... participation from existing investors TDF Ventures and WSJ ... to continue its triple-digit growth and accelerate its ...
(Date:3/2/2016)... March 2, 2016 ... the "Global Biometrics as a Service ... --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has ... Biometrics as a Service Market 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) ...
Breaking Biology News(10 mins):
(Date:4/27/2016)... ... April 27, 2016 , ... ... its Scientific Advisory Board. Dr. Lamka will assist PathSensors in expanding the use ... , PathSensors deploys the CANARY® test platform for the detection of harmful pathogens, ...
(Date:4/27/2016)... MedDay, a biotechnology company focused on ... of Catherine Moukheibir as Chairman of its Board of Directors. ... Jacques Garaud , who contributed to the rapid development of ... Catherine started her career in strategy consulting and investment ... London .  She held C-Suite level roles in some ...
(Date:4/26/2016)... ... ... The European Patent Office (EPO) today announced that U.S. Biophysicist ... Inventor Award 2016 in the category "Non-European countries." The winners of the 11th edition ... on June 9th. , The human capacity to walk with fluidity is the sum ...
(Date:4/26/2016)... , ... April 26, 2016 , ... BioFactura, Inc ... Series A round of financing. Healthy investor interest drove significant oversubscription of the ... generic biologics, known as biosimilars, to the advanced preclinical stages. , Chief Executive Officer ...
Breaking Biology Technology: